EMA on J&J COVID-19 vaccine: benefit-risk analysis remains positive; possible link with very rare cases of blood clots
The European Medicines Agency’s safety committee (PRAC) says a warning about unusual blood clots with low blood platelets should be added to the product information for COVID-19 Vaccine Janssen: but says the benefit-risk analysis for the vaccine remains...